Randomized, double-blind, placebo-controlled, multi-center, sequential cohort study to evaluate the effect of SLV320 in addition to chronic furosemide treatment on renal function in subjects with congestive heart failure and impaired renal function.
Latest Information Update: 10 Nov 2021
Price :
$35 *
At a glance
- Drugs SLV 320 (Primary)
- Indications Heart failure
- Focus Biomarker; Therapeutic Use
- Sponsors Abbott Healthcare Products
- 25 Mar 2008 Status changed from suspended to discontinued.
- 15 Feb 2008 Status changed from recruiting to suspended, as reported in ClinicalTrials.gov.
- 20 Dec 2007 New trial record.